ClinicalTrials.gg
CompletedNCT06494644Updated May 31, 2025

A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.

A Phase 1 interventional study of AZD6793 and Itraconazole in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
184th of 194
17 · median 137
Started
2024
with 16 others
Phase 1
42 of 284
none open now
Registered
262nd of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 184th largest by enrollment of the 194 interventional ones that give a count, is one of 17 that started in 2024, is one of 42 in phase 1, and was the 262nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The study will evaluate the pharmacokinetics (PK) of AZD6793 when administered alone and in combination with itraconazole in healthy adult participants.

Read the detailed description

This is a single-group study with a duration of up to 8 weeks (maximum of 53 days) including Screening, Period 1, Period 2, Period 3 and Follow-up.

The study will comprise of:

  • A screening period of 27 days
  • Three treatment periods: Period 1 (Day -1 to Day 3): Single dose AZD6793 will be administered on Day 1 followed by a 3-day washout period; Period 2 (Day 4 to Day 7): Itraconazole will be administered from Day 4 through Day 7, starting with 2 doses of 200 mg itraconazole given 12 hours apart on Day 4, then 200 mg itraconazole will be given once a day on Day 5 through Day 7. Period 3 (Day 8 to Day 11): On Day 8, participants will be co-administered with AZD6793 and 200 mg itraconazole. Administration of 200 mg itraconazole will continue on Day 9 and Day 10. Participants will be discharged from the clinic on Day 11.
  • A Follow-up Visit 10-15 days after the last itraconazole dose in Period 3.
03

Conditions studied

  • Healthy Participants

Keywords

  • AZD6793
  • Itraconazole
  • Chronic obstructive pulmonary disease
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Female participants must have a negative pregnancy test at screening and on admission and must not be lactating.
  • Females of must not be lactating and, if heterosexually active, must agree to use with their partner an approved method of highly effective to avoid pregnancy.
  • Females of non-childing potential must be confirmed at the Screening Visit.
  • Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods from Screening visit until 3 months after Follow-up visit.
  • Participants with between 18 and 30 kg/m², and at least 50 kg at the Screening Visit.
  • Participants should be fully/sufficiently vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as per current local regulations.

Main Exclusion Criteria:

  • History of any disease or disorder which may either put the participant at risk because of participation in the study or influence the results or the participant's ability to participate in the study.
  • History or presence of gastrointestinal, hepatic, renal, or pancreatic disease, or any other clinically significant disease or disorder known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • History of clinically significant chronic or active hematologic disease.
  • Diagnosis or history of immunodeficiency or increased susceptibility to severe infection, or a clinically significant infection within 4 weeks of the Screening Visit.
  • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study drug.
  • Any laboratory values with deviations at the Screening Visit or on admission to the Clinical Unit. Abnormal values may be repeated at the discretion of the Investigator: (ALT) > Upper Limit Normal (), Aspartate Transaminase (AST) > ULN, WBC count \< Lower limit normal (LLN), Neutrophils > ULN or \< LLN, \< 120 g/L, > ULN, Urinary albumin to creatinine ratio abnormal (≥ 3.4 mg/mmol), eGlomerular filtration rate () \< 85 mL/min/1.73 m² calculated using the CKD-EPI equation (eGFR will only be assessed at Screening).
  • Any clinically important abnormalities in clinical chemistry, haematology, or urinalysis results at the screening.
  • Positive or indeterminate QuantiFERON® TB test at the Screening Visit.
  • Any positive result on screening for serum surface antigen, antibody, or (HIV).
  • Participants with a history or presence of vitiligo or significant (in the opinion of the investigator) skin depigmentation for any cause including drugs.
  • Any clinically significant abnormal finding in vital signs, at the Screening Visit and/or on admission to the Clinical Unit.
  • Any clinically important abnormalities in rhythm, conduction or morphology of the resting (ECG) and any clinically important abnormalities in the 12 lead ECG.
  • Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening.
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
  • Positive screen for drugs of abuse, alcohol, or cotinine (nicotine) at screening visit or on admission to the Clinical Unit.
  • History or presence of severe allergy/.
  • Excessive intake of caffeine-containing drinks or food.
  • Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of the study drug.
  • Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, mega dose vitamins (intake of >3 times the recommended daily dose) and minerals during the 2 weeks or 5 half-lives of the medication, whichever is longer, prior to the first administration of study drug. The use of hormonal replacement therapy for females is not permitted.
  • Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days or 5 half-lives (whichever is longest) of the first administration of study intervention in this study.
  • Participants who have previously received AZD6793.
  • Vulnerable participants.
  • Participant has a positive test result for SARS-CoV-2 via RT-PCR on admission to the Clinical Unit.
  • Participant has clinical signs and symptoms consistent with Coronavirus disease 2019 (COVID-19).
  • Participant who had severe course of COVID-19.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    AZD6793 and Itraconazole

    Participants will receive a single dose of AZD6793 on Day 1. On Day 4, the participant will receive 2 doses of 200 mg itraconazole 12 hours apart followed by a single dose of 200 mg itraconazole from Days 5 to 7. On Day 8, participants will receive a combined dose of AZD6793 and 200 mg itraconazole. On Day 9 and Day 10, the participants will receive a single dose of 200 mg itraconazole.

    Drug: AZD6793 · Drug: Itraconazole · Drug: AZD6793+ Itraconazole

Interventions

  • Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.

  • Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.

  • DrugAZD6793+ Itraconazole

    Drug pages: AZD6793 · Itraconazole

    Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.

06

What researchers measure

Primary outcomes

  1. Maximum plasma drug concentration (Cmax)

    The effect of itraconazole on the single-dose Cmax of AZD6793 will be evaluated in healthy participants.

    Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11

  2. Area under plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)

    The effect of itraconazole on the single-dose AUClast of AZD6793 will be evaluated in healthy participants.

    Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11

  3. Area under plasma concentration-time curve from time 0 to infinity (AUCinf)

    The effect of itraconazole on the single-dose AUCinf of AZD6793 will be evaluated in healthy participants.

    Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11

  4. Apparent total body clearance (CL/F)

    The effect of itraconazole on the single-dose CL/F of AZD6793 will be evaluated in healthy participants.

    Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11

  5. Terminal elimination half-life (t1/2λz)

    The effect of itraconazole on the single-dose t1/2λz of AZD6793 will be evaluated in healthy participants.

    Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11

  6. Time to reach maximum observed concentration (tmax)

    The effect of itraconazole on the single-dose tmax of AZD6793 will be evaluated in healthy participants.

    Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11

  7. Apparent volume of distribution during the terminal phase (Vz/F)

    The effect of itraconazole on the single-dose Vz/F of AZD6793 will be evaluated in healthy participants.

    Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11

  8. Ratio Area under plasma concentration-time curve from time 0 to infinity (RAUCinf)

    The effect of itraconazole on the single-dose RAUCinf of AZD6793 will be evaluated in healthy participants.

    Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11

  9. Ratio Area under plasma concentration-time curve from time 0 to the last quantifiable concentration (RAUClast)

    The effect of itraconazole on the single-dose RAUClast of AZD6793 will be evaluated in healthy participants.

    Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11

  10. Ratio Maximum plasma drug concentration (RCmax)

    The effect of itraconazole on the single-dose RCmax of AZD6793 will be evaluated in healthy participants.

    Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11

Secondary outcomes

  1. Number of participants with adverse events

    The safety and tolerability after administration of AZD6793 with itraconazole will be evaluated.

    Time frame: From first dose (Day 1) until Follow-up (10-15 days post last itraconazole dose)

07

Study locations

1 site
  • Research Site
    Berlin, 14050, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Oct 2024, 2 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 2 months is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 10, 2024
StartActual
Jul 23, 2024
Primary completionActual
Oct 5, 2024
CompletionActual
Oct 5, 2024
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06494644
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 10, 2024
Start date
Jul 23, 2024
Primary completion
Oct 5, 2024
Completion
Oct 5, 2024
Last update
May 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD6793

Start the discussion